Study compares quality of life for boys on different hemophilia drugs
NCT ID NCT06191068
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed observational study looked at boys aged 7-18 with moderate or severe hemophilia A in Canadian treatment centres. Researchers compared quality of life and caregiver burden between those receiving an intravenous factor replacement product and those on a subcutaneous non-factor product. Participants and their caregivers filled out questionnaires at several time points to see if one treatment approach was linked to better well-being.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Hospital for Sick Children
Toronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a clotting boost make surgery safer for hemophilia patients?
- A facelift without the bruising? tranexamic acid put to the test.
- Deep gum cleaning may boost quality of life for hemophilia patients
- Can a video call replace the clinic for hemophilia pain relief?
- Experimental drug aims to reverse liver damage in rare triple condition
- Monthly shot could free kids with hemophilia from frequent infusions